{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:25:58Z","timestamp":1792787158844,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jacadv.2025.102462","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T06:38:38Z","timestamp":1768718318000},"page":"102462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Sodium Glucose Co-Transporter 2 Inhibitors in Patients With Heart Failure and Transcatheter Aortic Valve Replacement"],"prefix":"10.1016","volume":"5","author":[{"given":"Farah","family":"Yasmin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ahmed Ali","family":"Fahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-2030","authenticated-orcid":false,"given":"Muhammad Sohaib","family":"Asghar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqas","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Chadi","family":"Alraies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.jacadv.2025.102462_bib1","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa1814052","article-title":"Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients","volume":"380","author":"Mack","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102462_bib2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"Authors\/Task Force Members","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"10166","key":"10.1016\/j.jacadv.2025.102462_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jacadv.2025.102462_bib4","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"issue":"14","key":"10.1016\/j.jacadv.2025.102462_bib5","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa2500366","article-title":"Dapagliflozin in patients undergoing transcatheter aortic-valve implantation","volume":"392","author":"Raposeiras-Roubin","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102462_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","article-title":"A review of uses of health care utilization databases for epidemiologic research on therapeutics","volume":"58","author":"Schneeweiss","year":"2005","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102462_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2967\/jnmt.119.227819","article-title":"Review of HIPAA, part 1: history, protected health information, and privacy and security rules","volume":"47","author":"Moore","year":"2019","journal-title":"J Nucl Med Technol"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102462_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.31486\/toj.19.0095","article-title":"Exemptions and limited institutional review board review: a practical look at the 2018 common rule requirements for exempt research","volume":"20","author":"Walch-Patterson","year":"2020","journal-title":"Ochsner J"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102462_bib9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102462_bib10","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/sim.6004","article-title":"A comparison of 12 algorithms for matching on the propensity score","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102462_bib11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-Value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"18_Supplement","key":"10.1016\/j.jacadv.2025.102462_bib12","first-page":"B9","article-title":"TCT-184 comparative outcomes of SGLT2 inhibitors in patients undergoing transcatheter aortic valve replacement","volume":"84","author":"Thakkar","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102462_bib13","article-title":"B-85 | clinical efficacy of SGLT2 inhibitors in post transcatheter aortic valve replacement patients: a global retrospective Study","volume":"4","author":"Hanif","year":"2025","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"issue":"12_Supplement","key":"10.1016\/j.jacadv.2025.102462_bib14","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0735-1097(25)01549-9","article-title":"Impact of sodium-glucose cotransport-2 (sglt2) inhibitors on clinical outcomes in patients after transcatheter aortic valve replacement","volume":"85","author":"Dimala","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.jacadv.2025.102462_bib15","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jacadv.2025.102462_bib16","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jacadv.2025.102462_bib17","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jacadv.2025.102462_bib18","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25008919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25008919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T03:48:09Z","timestamp":1772509689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25008919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2772963X25008919"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102462","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium Glucose Co-Transporter 2 Inhibitors in Patients With Heart Failure and Transcatheter Aortic Valve Replacement","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102462","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102462"}}